5-bromo-N-[2-(6,7-dimethyl-2-oxo-1H-quinolin-3-yl)ethyl]-2-furancarboxamide profile

ID Source	ID
PubMed CID	3241566
CHEMBL ID	1439940
CHEBI ID	109407

Synonym
REGID4247347
EU-0091641
5-bromo-n-[2-(6,7-dimethyl-2-oxo-1,2-dihydroquinolin-3-yl)ethyl]-2-furamide
MLS000090992
smr000025585
zinc04004240 ,
CHEBI:109407
AB00669240-01
5-bromo-n-[2-(6,7-dimethyl-2-oxo-1h-quinolin-3-yl)ethyl]furan-2-carboxamide
AKOS024586897
HMS2303P23
CCG-28169
851096-42-9
F0611-0047
CHEMBL1439940
Q27188527
5-bromo-n-[2-(6,7-dimethyl-2-oxo-1h-quinolin-3-yl)ethyl]-2-furancarboxamide

Class	Description
quinolines	A class of aromatic heterocyclic compounds each of which contains a benzene ring ortho fused to carbons 2 and 3 of a pyridine ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, HADH2 protein	Homo sapiens (human)	Potency	31.6228	0.0251	20.2376	39.8107	AID893
Chain B, HADH2 protein	Homo sapiens (human)	Potency	31.6228	0.0251	20.2376	39.8107	AID893
Chain A, 2-oxoglutarate Oxygenase	Homo sapiens (human)	Potency	28.1838	0.1778	14.3909	39.8107	AID2147
glp-1 receptor, partial	Homo sapiens (human)	Potency	0.5012	0.0184	6.8060	14.1254	AID624417
phosphopantetheinyl transferase	Bacillus subtilis	Potency	28.1838	0.1413	37.9142	100.0000	AID1490
TDP1 protein	Homo sapiens (human)	Potency	29.0929	0.0008	11.3822	44.6684	AID686978; AID686979
Microtubule-associated protein tau	Homo sapiens (human)	Potency	14.1254	0.1800	13.5574	39.8107	AID1460
thioredoxin glutathione reductase	Schistosoma mansoni	Potency	35.4813	0.1000	22.9075	100.0000	AID485364
Smad3	Homo sapiens (human)	Potency	5.0119	0.0052	7.8098	29.0929	AID588855
aldehyde dehydrogenase 1 family, member A1	Homo sapiens (human)	Potency	23.7558	0.0112	12.4002	100.0000	AID1030
regulator of G-protein signaling 4	Homo sapiens (human)	Potency	50.1187	0.5318	15.4358	37.6858	AID504845
nonstructural protein 1	Influenza A virus (A/WSN/1933(H1N1))	Potency	10.0000	0.2818	9.7212	35.4813	AID2326
67.9K protein	Vaccinia virus	Potency	31.6228	0.0001	8.4406	100.0000	AID720580
euchromatic histone-lysine N-methyltransferase 2	Homo sapiens (human)	Potency	17.7828	0.0355	20.9770	89.1251	AID504332
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1	Homo sapiens (human)	Potency	15.8489	0.0018	15.6638	39.8107	AID894
ubiquitin carboxyl-terminal hydrolase 2 isoform a	Homo sapiens (human)	Potency	12.5893	0.6561	9.4520	25.1189	AID927
Vpr	Human immunodeficiency virus 1	Potency	0.8913	1.5849	19.6264	63.0957	AID651644
Guanine nucleotide-binding protein G	Homo sapiens (human)	Potency	25.1189	1.9953	25.5327	50.1187	AID624287
Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)	Potency	12.5893	1.5849	13.0043	25.1189	AID927
TAR DNA-binding protein 43	Homo sapiens (human)	Potency	31.6228	1.7783	16.2081	35.4813	AID652104
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
negative regulation of inflammatory response to antigenic stimulus	Guanine nucleotide-binding protein G	Homo sapiens (human)
renal water homeostasis	Guanine nucleotide-binding protein G	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Guanine nucleotide-binding protein G	Homo sapiens (human)
regulation of insulin secretion	Guanine nucleotide-binding protein G	Homo sapiens (human)
cellular response to glucagon stimulus	Guanine nucleotide-binding protein G	Homo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathway	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
response to hypoxia	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
neutrophil mediated immunity	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
germinal center formation	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
positive regulation of leukocyte chemotaxis	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
proteolysis	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
membrane protein ectodomain proteolysis	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
cell adhesion	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
Notch receptor processing	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
positive regulation of cell population proliferation	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
response to xenobiotic stimulus	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
positive regulation of T cell chemotaxis	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
protein processing	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
signal release	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
B cell differentiation	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
positive regulation of cell growth	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
positive regulation of cell migration	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathway	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
response to lipopolysaccharide	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
positive regulation of chemokine production	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
positive regulation of tumor necrosis factor production	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
regulation of mast cell apoptotic process	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
T cell differentiation in thymus	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
cell adhesion mediated by integrin	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
wound healing, spreading of epidermal cells	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
amyloid precursor protein catabolic process	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
positive regulation of blood vessel endothelial cell migration	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
positive regulation of cyclin-dependent protein serine/threonine kinase activity	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
positive regulation of epidermal growth factor-activated receptor activity	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathway	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
spleen development	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
cell motility	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
defense response to Gram-positive bacterium	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
cellular response to high density lipoprotein particle stimulus	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
commissural neuron axon guidance	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
negative regulation of cold-induced thermogenesis	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
positive regulation of G1/S transition of mitotic cell cycle	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
positive regulation of tumor necrosis factor-mediated signaling pathway	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
positive regulation of vascular endothelial cell proliferation	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
Notch signaling pathway	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
negative regulation of protein phosphorylation	TAR DNA-binding protein 43	Homo sapiens (human)
mRNA processing	TAR DNA-binding protein 43	Homo sapiens (human)
RNA splicing	TAR DNA-binding protein 43	Homo sapiens (human)
negative regulation of gene expression	TAR DNA-binding protein 43	Homo sapiens (human)
regulation of protein stability	TAR DNA-binding protein 43	Homo sapiens (human)
positive regulation of insulin secretion	TAR DNA-binding protein 43	Homo sapiens (human)
response to endoplasmic reticulum stress	TAR DNA-binding protein 43	Homo sapiens (human)
positive regulation of protein import into nucleus	TAR DNA-binding protein 43	Homo sapiens (human)
regulation of circadian rhythm	TAR DNA-binding protein 43	Homo sapiens (human)
regulation of apoptotic process	TAR DNA-binding protein 43	Homo sapiens (human)
negative regulation by host of viral transcription	TAR DNA-binding protein 43	Homo sapiens (human)
rhythmic process	TAR DNA-binding protein 43	Homo sapiens (human)
regulation of cell cycle	TAR DNA-binding protein 43	Homo sapiens (human)
3'-UTR-mediated mRNA destabilization	TAR DNA-binding protein 43	Homo sapiens (human)
3'-UTR-mediated mRNA stabilization	TAR DNA-binding protein 43	Homo sapiens (human)
nuclear inner membrane organization	TAR DNA-binding protein 43	Homo sapiens (human)
amyloid fibril formation	TAR DNA-binding protein 43	Homo sapiens (human)
regulation of gene expression	TAR DNA-binding protein 43	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
G protein activity	Guanine nucleotide-binding protein G	Homo sapiens (human)
adenylate cyclase activator activity	Guanine nucleotide-binding protein G	Homo sapiens (human)
endopeptidase activity	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
metalloendopeptidase activity	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
Notch binding	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
interleukin-6 receptor binding	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
integrin binding	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
protein binding	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
peptidase activity	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
metallopeptidase activity	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
SH3 domain binding	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
cytokine binding	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
PDZ domain binding	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
tumor necrosis factor binding	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
metal ion binding	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
metalloendopeptidase activity involved in amyloid precursor protein catabolic process	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	TAR DNA-binding protein 43	Homo sapiens (human)
DNA binding	TAR DNA-binding protein 43	Homo sapiens (human)
double-stranded DNA binding	TAR DNA-binding protein 43	Homo sapiens (human)
RNA binding	TAR DNA-binding protein 43	Homo sapiens (human)
mRNA 3'-UTR binding	TAR DNA-binding protein 43	Homo sapiens (human)
protein binding	TAR DNA-binding protein 43	Homo sapiens (human)
lipid binding	TAR DNA-binding protein 43	Homo sapiens (human)
identical protein binding	TAR DNA-binding protein 43	Homo sapiens (human)
pre-mRNA intronic binding	TAR DNA-binding protein 43	Homo sapiens (human)
molecular condensate scaffold activity	TAR DNA-binding protein 43	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
plasma membrane	Guanine nucleotide-binding protein G	Homo sapiens (human)
cell-cell junction	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
focal adhesion	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
ruffle membrane	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
Golgi membrane	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
cytoplasm	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
endoplasmic reticulum lumen	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
cytosol	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
plasma membrane	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
cell surface	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
actin cytoskeleton	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
membrane	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
apical plasma membrane	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
membrane raft	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
plasma membrane	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
intracellular non-membrane-bounded organelle	TAR DNA-binding protein 43	Homo sapiens (human)
nucleus	TAR DNA-binding protein 43	Homo sapiens (human)
nucleoplasm	TAR DNA-binding protein 43	Homo sapiens (human)
perichromatin fibrils	TAR DNA-binding protein 43	Homo sapiens (human)
mitochondrion	TAR DNA-binding protein 43	Homo sapiens (human)
cytoplasmic stress granule	TAR DNA-binding protein 43	Homo sapiens (human)
nuclear speck	TAR DNA-binding protein 43	Homo sapiens (human)
interchromatin granule	TAR DNA-binding protein 43	Homo sapiens (human)
nucleoplasm	TAR DNA-binding protein 43	Homo sapiens (human)
chromatin	TAR DNA-binding protein 43	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (14)

Assay ID	Title	Year	Journal	Article
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID652178	Confirmed Agonists of Novel Allosteric Modulators of the M1 Muscarinic Receptor	2013	Molecules (Basel, Switzerland), Jan-08, Volume: 18, Issue:1	Benchmarking ligand-based virtual High-Throughput Screening with the PubChem database.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (16.67)	29.6817
2010's	4 (66.67)	24.3611
2020's	1 (16.67)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	6 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
minoxidil Minoxidil: A potent direct-acting peripheral vasodilator (VASODILATOR AGENTS) that reduces peripheral resistance and produces a fall in BLOOD PRESSURE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p371). minoxidil : A pyrimidine N-oxide that is pyrimidine-2,4-diamine 3-oxide substituted by a piperidin-1-yl group at position 6.	2.08	1	dialkylarylamine; tertiary amino compound
spiperone Spiperone: A spiro butyrophenone analog similar to HALOPERIDOL and other related compounds. It has been recommended in the treatment of SCHIZOPHRENIA.. spiperone : An azaspiro compound that is 1,3,8-triazaspiro[4.5]decane which is substituted at positions 1, 4, and 8 by phenyl, oxo, and 4-(p-fluorophenyl)-4-oxobutyl groups, respectively.	2.08	1	aromatic ketone; azaspiro compound; organofluorine compound; piperidines; tertiary amino compound	alpha-adrenergic antagonist; antipsychotic agent; dopaminergic antagonist; psychotropic drug; serotonergic antagonist
pilocarpine hydrochloride pilocarpine hydrochloride : The hydrochloride salt of (+)-pilocarpine, a medication used to treat increased pressure inside the eye and dry mouth.	2.08	1	hydrochloride
rhein [no description available]	2.08	1	dihydroxyanthraquinone
bethanechol chloride bethanechol chloride : The chloride salt of bethanechol. A slowly hydrolysed muscarinic agonist with no nicotinic effects, it is used to increase smooth muscle tone, as in the gastrointestinal tract following abdominal surgery, treatment of gastro-oesophageal reflux disease, and as an alternative to catheterisation in the treatment of non-obstructive urinary retention.	2.08	1	carbamate ester; chloride salt; quaternary ammonium salt	muscarinic agonist
n-(cyclohexylthio)phthalimide N-(cyclohexylthio)phthalimide: water pollutant	2.08	1
oxcarbazepine Oxcarbazepine: A carbamazepine derivative that acts as a voltage-gated sodium channel blocker. It is used for the treatment of PARTIAL SEIZURES with or without secondary generalization. It is also an inducer of CYTOCHROME P-450 CYP3A4.. oxcarbazepine : A dibenzoazepine derivative, having a carbamoyl group at the ring nitrogen, substituted with an oxo group at C-4 of the azepeine ring which is also hydrogenated at C-4 and C-5. It is a anticholinergic anticonvulsant and mood stabilizing drug, used primarily in the treatment of epilepsy.	2.08	1	cyclic ketone; dibenzoazepine	anticonvulsant; drug allergen
ergocornine ergocornine: a component of ergotoxine; minor descriptor (75-86); on-line & INDEX MEDICUS search ERGOLINES (75-86); RN given refers to ((5'alpha)-isomer). ergocornine : Ergotaman bearing a hydroxy group at the 12' position, isopropyl groups at the 2' and 5'alpha positions, and oxo groups at positions 3', 6', and 18. It is a natural ergot alkaloid.	2.08	1	ergot alkaloid
butyrylcholine chloride [no description available]	2.08	1
monopentyl phthalate monopentyl phthalate : A phthalic acid monoester obtained by formal condensation of one of the carboxy groups of phthalic acid with the hydroxy group of pentanol.	2.08	1	phthalic acid monoester	anti-estrogen; rat metabolite; xenobiotic metabolite
7-amino-4-trifluoromethylcoumarin coumarin 151: structure in first source	2.08	1	7-aminocoumarins	fluorochrome
alpha-(n6-adenyl)styrene oxide alpha-(N6-adenyl)styrene oxide: structure given in first source; RN given refers to compound with no isomeric designation	2.08	1
2-[[2-[[4-(2-furanylmethyl)-5-(phenylmethyl)-1,2,4-triazol-3-yl]thio]-1-oxoethyl]amino]-5,6-dihydro-4H-cyclopenta[b]thiophene-3-carboxamide [no description available]	2.08	1	aromatic amide; thiophenes
1-(1,3-benzodioxol-5-ylmethyl)-3-hydroxy-3-[2-(4-methylphenyl)-2-oxoethyl]-2-indolone [no description available]	2.08	1	aromatic ketone
6-ethyl-N-[2-(4-methoxyphenyl)ethyl]-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine [no description available]	2.08	1	triazolopyrimidines
7-[2-hydroxy-3-(2-methylphenoxy)propyl]-3-methyl-8-(propan-2-ylthio)purine-2,6-dione [no description available]	2.08	1	oxopurine
2-[[5-(1-benzotriazolylmethyl)-1,3,4-oxadiazol-2-yl]thio]-N-[(4-fluorophenyl)methyl]-N-phenylacetamide [no description available]	2.08	1	benzotriazoles
3-[(1-cyclopentyl-5-tetrazolyl)-[4-(2-methoxyphenyl)-1-piperazinyl]methyl]-7-methyl-1H-quinolin-2-one [no description available]	2.08	1	piperazines
3-[[2-[[5-[(4-cyanophenoxy)methyl]-4-phenyl-1,2,4-triazol-3-yl]thio]-1-oxoethyl]amino]benzoic acid methyl ester [no description available]	2.08	1	amidobenzoic acid
[5-(2-furanyl)-7-(trifluoromethyl)-2-pyrazolo[1,5-a]pyrimidinyl]-[4-(2-pyridinyl)-1-piperazinyl]methanone [no description available]	2.08	1	piperazines; pyridines
N-[2-[(3-cyano-6-ethoxy-2-quinolinyl)amino]ethyl]propanamide [no description available]	2.08	1	aminoquinoline
4-[3-(1,3-dioxo-2-isoindolyl)propylamino]-2-methylisoindole-1,3-dione [no description available]	2.08	1	phthalimides
9-[3-(4-acetyl-3,5-dimethyl-1-pyrazolyl)-2-hydroxypropyl]-6-methyl-3,4-dihydro-2H-carbazol-1-one [no description available]	2.08	1	carbazoles
1-phenyl-4-[[1-(phenylmethyl)-5-tetrazolyl]-(3-pyridinyl)methyl]piperazine [no description available]	2.08	1	piperazines
1-[(5,8-dimethyl-2-oxo-1H-quinolin-3-yl)methyl]-1-(2-furanylmethyl)-3-phenylurea [no description available]	2.08	1	quinolines
N-(2-furanylmethyl)-2-[(4-methoxyphenyl)sulfonylamino]benzamide [no description available]	2.08	1	sulfonamide
N-methyl-N-[5-(5-methyl-2-pyrazinyl)-1,3,4-thiadiazol-2-yl]-2-oxolanecarboxamide [no description available]	2.08	1	pyrazines
2-[[2-(3,4-dihydro-2H-quinolin-1-yl)-2-oxoethyl]thio]-3-ethyl-4-quinazolinone [no description available]	2.08	1	quinazolines
2-[[5-(4-methylphenyl)-3-thiazolo[2,3-c][1,2,4]triazolyl]thio]-N-(6-methyl-2-pyridinyl)acetamide [no description available]	2.08	1	organic heterobicyclic compound; organonitrogen heterocyclic compound; organosulfur heterocyclic compound
4-amino-N5-[2-(2-methoxyethylamino)-1-(5-methyl-2-furanyl)-2-oxoethyl]-N5-(thiophen-2-ylmethyl)isothiazole-3,5-dicarboxamide [no description available]	2.08	1	organonitrogen compound; organooxygen compound
pilocarpine nitrate [no description available]	2.08	1
7-diethylaminocoumarin-3-carboxylic acid [no description available]	2.08	1
5-(4-methoxyphenyl)-7-(4-methylphenyl)-1,7-dihydrotetrazolo[1,5-a]pyrimidine [no description available]	2.08	1	methoxybenzenes
cyclopropanecarboxylic acid [5-(6-amino-5-cyano-3-methyl-2,4-dihydropyrano[2,3-c]pyrazol-4-yl)-2-ethoxyphenyl] ester [no description available]	2.08	1	pyranopyrazole
2-cyano-2-[3-(4-morpholinyl)-2-quinoxalinyl]acetic acid cyclohexyl ester [no description available]	2.08	1	quinoxaline derivative
2-(3-methylphenyl)sulfonyl-2-[3-(1-pyrrolidinyl)-2-quinoxalinyl]acetonitrile [no description available]	2.08	1	quinoxaline derivative
5-(3-methoxyphenyl)-N-(2-oxolanylmethyl)-7-(trifluoromethyl)-3-pyrazolo[1,5-a]pyrimidinecarboxamide [no description available]	2.08	1	pyrimidines
2-(4-bromophenyl)-4-methyl-1H-pyrazol-5-one [no description available]	2.08	1	pyrazoles; ring assembly
2-[(4-fluoro-3-methylphenyl)sulfonylamino]acetic acid [no description available]	2.08	1	sulfonamide
4-(1H-benzimidazol-2-yl)quinoline [no description available]	2.08	1	quinolines
2-[[2-(5,6-dimethyl-1-benzimidazolyl)-1-oxoethyl]amino]benzoic acid methyl ester [no description available]	2.08	1	amidobenzoic acid
1-(4-ethylphenyl)-N-(3-pyridinylmethyl)methanamine [no description available]	2.08	1	aromatic amine
1-(4-ethoxyphenyl)-3-(6-quinoxalinyl)urea [no description available]	2.08	1	quinoxaline derivative
3-methyl-5-propyl-7-furo[3,2-g][1]benzopyranone [no description available]	2.08	1	psoralens
4-(1,3-benzothiazol-2-yl)-N-phenyl-1-piperazinecarboxamide [no description available]	2.08	1	N-arylpiperazine
2-[4-(pyridin-4-ylmethylsulfamoyl)phenoxy]acetic acid methyl ester [no description available]	2.08	1	monocarboxylic acid
5-bromo-N-(pyridin-4-ylmethyl)-2-thiophenesulfonamide [no description available]	2.08	1	thiophenes
LSM-16463 [no description available]	2.08	1	pyrazoles; ring assembly
4-[2-(9-methyl-6-indolo[3,2-b]quinoxalinyl)ethyl]morpholine [no description available]	2.08	1	quinoxaline derivative
4-[[[3-(4-morpholinylsulfonyl)phenyl]-oxomethyl]amino]benzoic acid ethyl ester [no description available]	2.08	1	benzamides
5-(2,3-dihydroindol-1-ylsulfonyl)-1,3-diethyl-2-benzimidazolone [no description available]	2.08	1	benzimidazoles
N-[2-(4-acetyl-1-piperazinyl)phenyl]-2-(5-methyl-2-propan-2-ylphenoxy)acetamide [no description available]	2.08	1	piperazines
N-(2-furanylmethyl)-2-imino-5-oxo-1-(2-phenylethyl)-3-dipyrido[1,2-d-3',4'-f]pyrimidinecarboxamide [no description available]	2.08	1	pyridopyrimidine
N-[2-[4-[(4-chlorophenyl)-oxomethyl]-1-piperazinyl]phenyl]-1,3-benzodioxole-5-carboxamide [no description available]	2.08	1	aromatic amide
[2-(4-methoxyphenyl)-6-methyl-4-quinolinyl]-(4-morpholinyl)methanone [no description available]	2.08	1	quinolines
2-(2-furanyl)-5-methyl-6-(phenylmethyl)-1H-[1,2,4]triazolo[1,5-a]pyrimidin-7-one [no description available]	2.08	1	triazolopyrimidines
1-[4-[(2-amino-5-thiazolyl)methyl]phenyl]ethanone [no description available]	2.08	1	aromatic ketone
N-[2-[4-[(4-chlorophenyl)-oxomethyl]-1-piperazinyl]phenyl]-2-benzofurancarboxamide [no description available]	2.08	1	aromatic amide; furans
2-(3,5-dimethylphenoxy)-N-[3-[5-(2-furanyl)-1,3,4-oxadiazol-2-yl]phenyl]acetamide [no description available]	2.08	1	anilide
5-(2-furanyl)-N-[1-[(2-methylphenyl)methyl]-3-pyrazolyl]-7-(trifluoromethyl)-3-pyrazolo[1,5-a]pyrimidinecarboxamide [no description available]	2.08	1	pyrazolopyrimidine
1,4-dioxa-8-azaspiro[4.5]decan-8-yl-(5,7-diphenyl-2-pyrazolo[1,5-a]pyrimidinyl)methanone [no description available]	2.08	1	pyrimidines
4-amino-2-[[4-(1-azepanylsulfonyl)phenyl]-oxomethyl]isoindole-1,3-dione [no description available]	2.08	1	phthalimides
N-(1,5-dimethyl-3-oxo-2-phenyl-4-pyrazolyl)-2-[(6-methyl-1H-benzimidazol-2-yl)thio]acetamide [no description available]	2.08	1	pyrazoles; ring assembly
2-(1-benzimidazolyl)acetic acid [2-[1-(4-methoxyphenyl)-2,5-dimethyl-3-pyrrolyl]-2-oxoethyl] ester [no description available]	2.08	1	alpha-amino acid ester
2-(3-oxo-2,4-dihydro-1H-quinoxalin-2-yl)-N-phenylacetamide [no description available]	2.08	1	amino acid amide
6-amino-5-cyano-4-(2,4-dimethoxyphenyl)-2-(2-ethoxy-2-oxoethyl)-4H-pyran-3-carboxylic acid ethyl ester [no description available]	2.08	1	dimethoxybenzene
2-chloro-5-[[2,3-dihydro-1,4-benzodioxin-3-yl(oxo)methyl]amino]benzoic acid methyl ester [no description available]	2.08	1	amidobenzoic acid
N-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-methoxy-4-propan-2-yloxybenzamide [no description available]	2.08	1	benzodioxine
3-(3,4-dihydro-2H-quinolin-1-ylmethyl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine [no description available]	2.08	1	quinolines
benzoic acid [5-(6-benzamido-9-purinyl)-3-fluoro-4-hydroxy-2-oxolanyl]methyl ester [no description available]	2.08	1	3'-deoxyribonucleoside; purines
2-(2,3-dihydro-1,4-benzodioxin-6-ylsulfonylamino)benzoic acid thiophen-2-ylmethyl ester [no description available]	2.08	1	benzoate ester
2-benzoyl-N-(6-methoxy-3-pyridinyl)-3,4-dihydro-1H-isoquinoline-3-carboxamide [no description available]	2.08	1	isoquinolines
3,5-dimethyl-1-phenyl-4-pyrazolecarboxylic acid [2-[4-amino-1-methyl-3-(2-methylpropyl)-2,6-dioxo-5-pyrimidinyl]-2-oxoethyl] ester [no description available]	2.08	1	pyrazoles; ring assembly
9-chloro-6-methylindolo[3,2-b]quinoxaline [no description available]	2.08	1	quinoxaline derivative
3-chloro-N-[2-[4-(4-fluorophenyl)-1-piperazinyl]-2-(3-pyridinyl)ethyl]benzamide [no description available]	2.08	1	piperazines
N-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-[3-(4-methoxyphenyl)-1,2,4-oxadiazol-5-yl]propanamide [no description available]	2.08	1	oxadiazole; ring assembly
2-cyclopentyl-4-[1,4-dioxa-8-azaspiro[4.5]decan-8-yl(oxo)methyl]-9-methyl-1-pyrido[3,4-b]indolone [no description available]	2.08	1	beta-carbolines
N-(3-chlorophenyl)-5-(1,4-dioxa-8-azaspiro[4.5]decan-8-ylsulfonyl)-3-methyl-2-benzofurancarboxamide [no description available]	2.08	1	aromatic amide; furans
[4-[6-(4-morpholinyl)-3-pyridazinyl]-1-piperazinyl]-(2-pyridin-4-yl-4-quinolinyl)methanone [no description available]	2.08	1	quinolines
N-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-(3-methyl-4-oxo-1-phthalazinyl)acetamide [no description available]	2.08	1	phthalazines
3-(2-chlorophenyl)-5-methyl-N-[3-(3-methyl-2-imidazo[1,2-a]pyrimidinyl)phenyl]-4-isoxazolecarboxamide [no description available]	2.08	1	aromatic amide
7-(5-chloro-2-methoxyanilino)-6-[(4-methoxyphenyl)methyl]-7H-pyrrolo[3,4-b]pyridin-5-one [no description available]	2.08	1	pyrrolopyridine
2-furanyl-[4-(4-tetrazolo[1,5-a]quinoxalinyl)-1-piperazinyl]methanone [no description available]	2.08	1	N-arylpiperazine
[4-(2-pyrimidinyl)-1-piperazinyl]-[1-[4-(2-pyrimidinyl)-1-piperazinyl]-4-isoquinolinyl]methanone [no description available]	2.08	1	piperazines; pyridines
N-[[4-(dimethylamino)phenyl]methyl]-3-ethyl-N-(2-furanylmethyl)-5-methyl-4-oxo-6-thieno[2,3-d]pyrimidinecarboxamide [no description available]	2.08	1	organic heterobicyclic compound; organonitrogen heterocyclic compound; organosulfur heterocyclic compound
N-(2,3-dimethylphenyl)-3-methyl-5-(4-morpholinylsulfonyl)-2-benzofurancarboxamide [no description available]	2.08	1	aromatic amide; furans
N-[(2-methyl-4-thiazolyl)methyl]-4-phenoxybenzenesulfonamide [no description available]	2.08	1	aromatic ether
4-[[3-[(2-furanylmethylamino)-oxomethyl]-7-methoxy-1-benzopyran-2-ylidene]amino]benzoic acid [no description available]	2.08	1	1-benzopyran
N-(2-furanylmethyl)-1-[2-(2-hydroxyethoxy)ethyl]-2-imino-10-methyl-5-oxo-3-dipyrido[3,4-c-1',2'-f]pyrimidinecarboxamide [no description available]	2.08	1	pyridopyrimidine
1-(2,1,3-benzothiadiazol-4-ylsulfonyl)-N-(2,3-dihydro-1,4-benzodioxin-3-ylmethyl)-3-piperidinecarboxamide [no description available]	2.08	1	benzodioxine
4-[4-oxo-2-[[2-oxo-2-[(phenylmethyl)amino]ethyl]thio]-3-quinazolinyl]-1-piperidinecarboxylic acid ethyl ester [no description available]	2.08	1	quinazolines
8-(2-propoxyphenyl)-7,8-dihydro-5H-[1,3]dioxolo[4,5-g]quinolin-6-one [no description available]	2.08	1	quinolines
N-[4-[5-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-3-yl]phenyl]-4-pyridinecarboxamide [no description available]	2.08	1	aromatic amide
3-(5,7-diphenyl-1,7-dihydro-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)-1-propanol [no description available]	2.08	1	triazolopyrimidines
methysergide maleate [no description available]	2.08	1	ergoline alkaloid
morin morin: a light yellowish pigment found in the wood of old fustic (Chlorophora tinctoria). morin : A pentahydroxyflavone that is 7-hydroxyflavonol bearing three additional hydroxy substituents at positions 2' 4' and 5.	2.08	1	7-hydroxyflavonol; pentahydroxyflavone	angiogenesis modulating agent; anti-inflammatory agent; antibacterial agent; antihypertensive agent; antineoplastic agent; antioxidant; EC 5.99.1.2 (DNA topoisomerase) inhibitor; hepatoprotective agent; metabolite; neuroprotective agent
N-(4-bromo-3-methylphenyl)-2,5-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine [no description available]	2.08	1	triazolopyrimidines
4-[[[2-(4-methoxyphenyl)-3-oxo-1H-isoindol-4-yl]-oxomethyl]amino]-1-piperidinecarboxylic acid ethyl ester [no description available]	2.08	1	isoindoles
1,5-dimethyl-4-oxo-N-[2-(3-thiophenyl)ethyl]-2-pyrrolo[3,2-c]quinolinecarboxamide [no description available]	2.08	1	pyrroloquinoline
4-[[[1-[[2-(3-chlorophenyl)-5-methyl-4-oxazolyl]methyl]-3-piperidinyl]-oxomethyl]amino]-1-piperidinecarboxylic acid ethyl ester [no description available]	2.08	1	1,3-oxazoles
1,5-dimethyl-4-oxo-N-[3-(4-propyl-1-piperazinyl)propyl]-2-pyrrolo[3,2-c]quinolinecarboxamide [no description available]	2.08	1	pyrroloquinoline
4-(4-tetrazolo[1,5-a]quinoxalinyl)morpholine [no description available]	2.08	1	quinoxaline derivative
1-cyclopentyl-1-[(4-oxo-1H-quinazolin-2-yl)methyl]-3-(phenylmethyl)urea [no description available]	2.08	1	quinazolines
7-hydroxyquinoline 7-hydroxyquinoline: structure in first source. quinolin-7-ol : A monohydroxyquinoline carrying a hydroxy substituent at position 7.	2.08	1	monohydroxyquinoline

Condition	Indicated	Relationship Strength	Studies	Trials
Innate Inflammatory Response [description not available]	0	2.05	1	0
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	0	2.05	1	0

5-bromo-N-[2-(6,7-dimethyl-2-oxo-1H-quinolin-3-yl)ethyl]-2-furancarboxamide

Cross-References

Synonyms (17)

Drug Classes (1)

Protein Targets (20)

Potency Measurements

Biological Processes (62)

Molecular Functions (25)

Ceullar Components (22)

Bioassays (14)

Research

Studies (6)

Market Indicators

Research Demand Index: 12.35

Study Types

5-bromo-N-[2-(6,7-dimethyl-2-oxo-1H-quinolin-3-yl)ethyl]-2-furancarboxamide

Cross-References

Synonyms (17)

Drug Classes (1)

Protein Targets (20)

Potency Measurements

Biological Processes (62)

Molecular Functions (25)

Ceullar Components (22)

Bioassays (14)

Research

Studies (6)

Market Indicators

Research Demand Index: 12.35

Study Types

Related Drugs (104)

Related Conditions (2)